NASDAQ:DARE - Dare Bioscience Stock Price, Price Target & More

$1.28 +0.47 (+58.02 %)

(As of 04/25/2018 10:30 AM ET)

Previous Close$0.81

Today's Range$0.95 - $1.33

52-Week Range$0.74 - $12.40

Volume8.53 million shs

Average Volume374,996 shs

Market Capitalization$9.45 million

P/E RatioN/A

Dividend YieldN/A

Beta2.86

About Dare Bioscience (NASDAQ:DARE)

Daré Bioscience, Inc. develops and commercializes product for women's reproductive health, Ovaprene. The company was incorporated in 2015 and is based in La Jolla, California.

Receive DARE News and Ratings via Email

Sign-up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorFinance

SymbolNASDAQ:DARE

CUSIPN/A

Webwww.darebioscience.com

Phone858-926-7655

Debt

Debt-to-Equity RatioN/A

Current Ratio8.69%

Quick Ratio8.69%

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash Flow$0.8889 per share

Price / Cash1.44

Book Value$2.20 per share

Price / Book0.58

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-11,500,000.00

Net MarginsN/A

Return on Equity-115.82%

Return on Assets-89.29%

Miscellaneous

Employees5

Outstanding Shares11,420,000

How to Become a New Pot Stock Millionaire

Dare Bioscience (NASDAQ:DARE) Frequently Asked Questions

What is Dare Bioscience's stock symbol?

Dare Bioscience trades on the NASDAQ under the ticker symbol "DARE."

How were Dare Bioscience's earnings last quarter?

Dare Bioscience (NASDAQ:DARE) released its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.48) by $0.08. View Dare Bioscience's Earnings History.

When is Dare Bioscience's next earnings date?

Dare Bioscience is scheduled to release their next quarterly earnings announcement on Friday, May, 11th 2018. View Earnings Estimates for Dare Bioscience.

Who are some of Dare Bioscience's key competitors?

Some companies that are related to Dare Bioscience include Capricor Therapeutics (CAPR), PLx Pharma (PLXP), Chiasma (CHMA), Evoke Pharma (EVOK), Egalet (EGLT), Benitec Biopharma (BNTC), Nemus Bioscience (NMUS), ProPhase Labs (PRPH), Lipocine (LPCN), TapImmune (TPIV), OvaScience (OVAS), Ceapro (CRPOF), Nuvo Pharmaceuticals (NRIFF), Provectus Biopharmaceuticals (PVCT) and Citius Pharmaceuticals (CTXR).

Who are Dare Bioscience's key executives?

Dare Bioscience's management team includes the folowing people:

Ms. Sabrina Martucci Johnson, Pres, CEO, Sec. & Director (Age 51)
Ms. Lisa Walters-Hoffert, Chief Financial Officer (Age 59)

Has Dare Bioscience been receiving favorable news coverage?

Media stories about DARE stock have trended somewhat positive recently, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dare Bioscience earned a daily sentiment score of 0.10 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 44.95 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Dare Bioscience?

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dare Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $1.28.

How big of a company is Dare Bioscience?

Dare Bioscience has a market capitalization of $9.45 million. Dare Bioscience employs 5 workers across the globe.

How can I contact Dare Bioscience?

Dare Bioscience's mailing address is 11119 NORTH TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected]

MarketBeat Community Rating for Dare Bioscience (DARE)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		189 (Vote Outperform)
Underperform Votes:		108 (Vote Underperform)
Total Votes:		297

MarketBeat's community ratings are surveys of what our community members think about Dare Bioscience and other stocks. Vote "Outperform" if you believe DARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DARE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Dare Bioscience (NASDAQ:DARE) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	N/A	N/A	N/A	Buy
Consensus Rating Score:	N/A	N/A	N/A	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	N/A	N/A	N/A	$6.00
Price Target Upside:	N/A	N/A	N/A	757.14% upside

Dare Bioscience (NASDAQ:DARE) Consensus Price Target History

Price Target History for Dare Bioscience (NASDAQ:DARE)

Dare Bioscience (NASDAQ:DARE) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
11/9/2016	Canaccord Genuity	Reiterated Rating	Buy	$6.00	N/A
10/23/2016	Roth Capital	Reiterated Rating	Buy	$2.50	N/A
10/19/2016	Leerink Swann	Reiterated Rating	Market Perform	$1.50	N/A
8/30/2016	Barclays	Lower Price Target	Overweight	$5.00 -> $2.00	N/A
8/18/2016	Wedbush	Downgrade	Outperform -> Neutral		N/A
8/18/2016	Janney Montgomery Scott	Downgrade	Buy -> Neutral		N/A

(Data available from 4/25/2016 forward)

Dare Bioscience (NASDAQ:DARE) Earnings History and Estimates Chart

Earnings by Quarter for Dare Bioscience (NASDAQ:DARE)

Dare Bioscience (NASDAQ DARE) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Actual Revenue	Release Link	Conference Call
5/11/2018
8/14/2017	Q2 2017		($1.42)	$0.64 million	View	N/A
5/12/2017	Q1 2017	($3.10)	($2.20)	$1.19 million	View	N/A
11/3/2016	Q3 2016	($4.30)	($3.60)		View	N/A
8/4/2016	Q216	($0.48)	($0.40)		View	N/A
5/2/2016	Q116	($0.43)	($0.49)		View	N/A
3/10/2016	Q415	($0.41)	($0.39)		View	Listen
11/16/2015	Q315	($0.41)	($0.39)		View	Listen
8/6/2015	Q215	($0.40)	($0.37)		View	N/A
5/6/2015	Q1 2015	($4.50)	($4.10)		View	N/A
3/19/2015	Q4 2014	($0.36)	($0.37)		View	N/A
11/13/2014	Q3 2014	($0.32)	($0.28)		View	N/A
8/12/2014	Q2 2014	($0.36)	($0.34)	$0.03 million	View	N/A
5/27/2014	Q1 2014	($3.52)	($3.70)	$0.05 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

Dare Bioscience (NASDAQ:DARE) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Dare Bioscience (NASDAQ DARE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.60%
Institutional Ownership Percentage: 4.25%

Insider Trading History for Dare Bioscience (NASDAQ:DARE)

Dare Bioscience (NASDAQ DARE) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/22/2016	David R Walt	Director	Buy	2,291	$2.08	$4,765.28	166,900
2/18/2016	David R. Walt	Director	Buy	8,960	$2.10	$18,816.00	165,200
2/16/2016	David R. Walt	Director	Buy	8,811	$2.00	$17,622.00	156,240
2/11/2016	David R. Walt	Director	Buy	8,850	$2.05	$18,142.50	147,429
2/9/2016	David R. Walt	Director	Buy	9,000	$2.15	$19,350.00	138,579
2/5/2016	David R. Walt	Director	Buy	8,563	$2.30	$19,694.90	129,579
2/3/2016	David R. Walt	Director	Buy	8,413	$2.32	$19,518.16	121,016
2/1/2016	David R. Walt	Director	Buy	5,700	$2.38	$13,566.00	112,603
1/28/2016	David R. Walt	Director	Buy	9,000	$2.46	$22,140.00	106,903
1/26/2016	David R. Walt	Director	Buy	8,800	$2.39	$21,032.00	97,903
1/25/2016	David R. Walt	Director	Buy	4,500	$2.35	$10,575.00	97,903
1/22/2016	David R. Walt	Director	Buy	9,000	$2.28	$20,520.00	89,103
1/20/2016	David R. Walt	Director	Buy	8,900	$2.43	$21,627.00	80,103
1/15/2016	David R. Walt	Director	Buy	8,572	$2.53	$21,687.16	71,203
1/13/2016	David R. Walt	Director	Buy	8,684	$2.79	$24,228.36	62,631
1/11/2016	David R. Walt	Director	Buy	8,855	$2.87	$25,413.85	53,947
1/7/2016	David R. Walt	Director	Buy	8,800	$2.95	$25,960.00	45,092
1/5/2016	David R. Walt	Director	Buy	8,801	$3.03	$26,667.03	36,292
11/30/2015	David R Walt	Director	Buy	5,374	$3.25	$17,465.50	17,491
11/27/2015	David R. Walt	Director	Buy	12,117	$3.32	$40,228.44	12,117
4/7/2015	Cvf, Llc	Major Shareholder	Buy	333,333	$6.00	$1,999,998.00
4/15/2014	Alan L Crane	Director	Buy	1,470,582	$7.00	$10,294,074.00
4/15/2014	Eli & Co Lilly	Major Shareholder	Buy	733,445	$7.00	$5,134,115.00
4/15/2014	Lux Capital Management, Llc	Insider	Buy	106,224	$7.00	$743,568.00

(Data available from 1/1/2013 forward)

Dare Bioscience (NASDAQ DARE) News Headlines

Source:

Date	Headline
	BRIEF-Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform To Daré Bioscience www.reuters.com - April 25 at 9:21 AM
	Daré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform globenewswire.com - April 25 at 9:21 AM
	BRIEF-Daré Bioscience Enters Into Exclusive Worldwide License Agreement For Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform www.reuters.com - April 25 at 9:21 AM
	Daré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform finance.yahoo.com - April 25 at 9:21 AM
	Dare Bioscience (DARE) Downgraded by ValuEngine www.americanbankingnews.com - April 14 at 2:31 PM
	Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US finance.yahoo.com - April 13 at 9:40 AM
	Form 3 Dare Bioscience, Inc. For: Apr 09 Filed by: Grossman Jessica D. www.streetinsider.com - April 12 at 10:09 AM
	Jessica Grossman, M.D., Joins Daré Bioscience Board of Directors finance.yahoo.com - April 11 at 9:56 AM
	Baystreet Staff - www.baystreet.ca - April 3 at 9:36 AM
	Dare Bioscience (DARE) Reports FY17 EPS Loss of $3.47 www.streetinsider.com - April 3 at 9:36 AM
	BRIEF-Daré Bioscience Says Intends To Communicate With U.S. FDA In Mid-2018 Regarding Phase 2b Study Of Topical Sildenafil www.reuters.com - April 2 at 4:37 PM
	Dare Bioscience, Inc. to Host Earnings Call finance.yahoo.com - April 2 at 4:37 PM
	Daré Bioscience, Inc. Reports 2017 Financial Results and Provides Business Update finance.yahoo.com - April 2 at 4:37 PM
	Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on ... globenewswire.com - March 30 at 9:24 AM
	Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on Monday, April 2, 2018 finance.yahoo.com - March 29 at 9:40 AM
	PLx Pharma (PLXP) & Dare Bioscience (DARE) Financial Analysis www.americanbankingnews.com - March 15 at 5:25 AM
	Dare Bioscience (DARE) Reports Exclusive Development, Option Agreement with Orbis Biosciences for Long-acting ... - StreetInsider.com www.streetinsider.com - March 14 at 10:17 AM
	Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting ... - GlobeNewswire (press release) globenewswire.com - March 14 at 10:17 AM
	Orbis Biosciences and Daré Bioscience Collaborate to Advance Innovation for Women's Reproductive Health www.bizjournals.com - March 12 at 11:15 AM
	Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting Injectable Contraceptive finance.yahoo.com - March 12 at 11:15 AM
	Reviewing Athenex (ATNX) and Dare Bioscience (DARE) www.americanbankingnews.com - March 10 at 3:22 PM
	Dare Bioscience (DARE) Presents At LD Micro Virtual Conference 2018 - Slideshow seekingalpha.com - March 8 at 5:31 PM
	Daré Bioscience, Inc. To Participate in the 30th Annual ROTH Conference finance.yahoo.com - March 5 at 9:30 AM
	Daré Bioscience, Inc. To Participate in the LD Micro Virtual Conference finance.yahoo.com - February 27 at 9:21 AM
	Daré Bioscience, Developing Products for Women, Analysts Target, Pipeline Review finance.yahoo.com - February 26 at 9:12 AM
	Daré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal Disorder finance.yahoo.com - February 23 at 9:14 AM
	Mid-Afternoon Market Update: Chegg Surges After Strong Q4 Results; Dare Bioscience Shares Slide - Nasdaq www.nasdaq.com - February 15 at 8:39 AM
	Dare Bioscience's stock plunges to pace all decliners after stock offering - MarketWatch www.marketwatch.com - February 15 at 8:39 AM
	BRIEF-Dare Bioscience Inc To Raise About $10.25 Mln www.reuters.com - February 13 at 4:21 PM
	Today’s Research Reports on Trending Tickers: Dare Bioscience and MannKind finance.yahoo.com - February 13 at 9:21 AM
	BRIEF-Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD www.reuters.com - February 12 at 9:11 AM
	Daré Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder finance.yahoo.com - February 12 at 9:10 AM
	Daré Bioscience, Inc. to Present at the 2018 BIO CEO & Investor Conference finance.yahoo.com - February 6 at 9:12 AM
	Dare Bioscience (DARE) vs. The Competition Head to Head Comparison www.americanbankingnews.com - January 13 at 9:36 PM
	Contrasting Dare Bioscience (DARE) & Its Competitors www.americanbankingnews.com - January 11 at 8:18 AM
	Form 8-K Dare Bioscience, Inc. For: Dec 29 - StreetInsider.com www.streetinsider.com - January 5 at 9:02 AM
	Cerulean Pharma (DARE) vs. Its Rivals Head to Head Analysis www.americanbankingnews.com - December 27 at 10:00 AM
	Reviewing Cerulean Pharma (DARE) & Its Peers www.americanbankingnews.com - December 17 at 1:28 PM
	Cerulean Pharma (DARE) Upgraded by ValuEngine to "Sell" www.americanbankingnews.com - December 9 at 12:08 PM
	Who Are The Major Shareholders Of Daré Bioscience Inc (DARE)? finance.yahoo.com - December 9 at 8:57 AM
	Daré Bioscience, Inc. to Present at the LD Micro 10th Annual Main Event Conference finance.yahoo.com - December 4 at 8:52 AM
	With An ROE Of 177.59%, Has Daré Bioscience Inc’s (DARE) Management Done A Good Job? finance.yahoo.com - November 30 at 5:49 PM
	Daré Bioscience Inc (DARE): Is Healthcare Attractive Relative To NasdaqCM Peers? finance.yahoo.com - October 20 at 7:17 PM
	Contrasting Cerulean Pharma (DARE) & Dynavax Technologies Corporation (DVAX) www.americanbankingnews.com - October 15 at 12:10 AM
	Daré Bioscience, Inc. to Present at the 2017 BIO Investor Forum finance.yahoo.com - October 10 at 3:30 PM
	Daré Bioscience, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference finance.yahoo.com - September 7 at 5:48 PM
	Daré Bioscience, Inc. to Present at the Liolios 6th Annual Gateway Conference finance.yahoo.com - August 30 at 6:51 PM
	Cerulean Pharma Inc. (DARE) Given Consensus Rating of "Hold" by Analysts www.americanbankingnews.com - August 18 at 3:02 AM
	Daré Bioscience, Inc. CEO Featured in San Diego Business Journal Article on Women Founders finance.yahoo.com - August 15 at 6:30 PM
	Daré Bioscience, Inc. Discusses Key Goals with Wall Street Analyzer finance.yahoo.com - August 3 at 7:10 PM

Dare Bioscience (NASDAQ:DARE) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Dare Bioscience (NASDAQ:DARE) Income Statement, Balance Sheet and Cash Flow Statement

Dare Bioscience (NASDAQ DARE) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff